Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2005
11/10/2005US20050250675 Ketospirocyclopropaneindene compounds; anticarcinogenic agents
11/10/2005US20050250674 Nutritional and food supplement preparation comprising creatine and orotic acid complexes, derivatives and analogs
11/10/2005US20050250673 Neurodegenerative disease treatment
11/10/2005US20050250672 Using antihyperplastic agent; diffusion through capillaries; imaging veins, arteries; side effect reduction; antitumor agents
11/10/2005US20050250671 Activators of peroxisome proliferator-activated receptor
11/10/2005US20050250196 Recombinant microorganisms expressing an oligosaccharide receptor mimic
11/10/2005US20050250163 Modulators of angiogenesis and tumorigenesis
11/10/2005US20050250160 Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
11/10/2005US20050250128 Membranes incorporating recognition moieties
11/10/2005US20050250114 Method for decreasing the number of free virus particles within the bodily fluids of a virally-infected mammal
11/10/2005US20050250105 Multiple viral replicon culture systems
11/10/2005US20050249831 Herbal extract comprising a mixture of saponins obtained from sapindus trifoliatus for anticonvulsant activity
11/10/2005US20050249827 Nutritional composition which promotes weight loss, burns calories, increases thermogenesis, supports energy metabolism and/or suppresses appetite
11/10/2005US20050249826 Orally administrabel composition for improving skin quality
11/10/2005US20050249823 Methods for the prevention or amelioration of neuropsychiatric and related diseases
11/10/2005US20050249822 Administration of cisplatin by inhalation
11/10/2005US20050249821 Nutritional supplement for treatment of ocular diseases
11/10/2005US20050249820 Nutritional supplement for the treatment and prevention of macular degeneration
11/10/2005US20050249818 Polycationic antimicrobial therapeutic
11/10/2005US20050249814 Solubility of hydrophobic drugs with a compound having a carboxylic acid moiety
11/10/2005US20050249812 Micronized organic preservative formulations
11/10/2005US20050249809 Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
11/10/2005US20050249808 NSAIDs compositions containing tartaric acid
11/10/2005US20050249806 Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
11/10/2005US20050249805 Compositions and methods for treating hepatitis C virus (HCV) infection
11/10/2005US20050249804 Stabilized short-course chemotherapy (SCC) anti-tuberculosis drug compositions
11/10/2005US20050249803 Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
11/10/2005US20050249797 Self forming, thermodynamically stable liposomes and their applications
11/10/2005US20050249796 Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
11/10/2005US20050249795 Gemcitabine compositions for better drug delivery
11/10/2005US20050249793 Athletic patch
11/10/2005US20050249788 Methods and compositions for reducing oxidative stress in an animal
11/10/2005US20050249787 Methods and compositions for reducing oxidative stress in an animal
11/10/2005US20050249786 Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
11/10/2005US20050249785 Use of melatonin-containing oral supplement with animals
11/10/2005US20050249783 Method of improving absorption of vitamin e by a pet animal
11/10/2005US20050249781 Antiobesity or antihyperlipidemic food, feeding stuff or supplement containing lysine
11/10/2005US20050249778 Carboxylated polysaccharides and method of preparation and use
11/10/2005US20050249770 Compositions and methods for treating or preventing inflammatory diseases
11/10/2005US20050249768 Environmentally safe insect repellent composition
11/10/2005US20050249761 Topical composition comprising at least one aryl oxime and bisabolol
11/10/2005US20050249760 Human body affinitive lubricating protective and repair gel
11/10/2005US20050249757 Pharmaceutical cream formulations
11/10/2005US20050249752 Vector for anti-hpv vaccine and transformed microorganism by the vector
11/10/2005US20050249718 Compositions and methods for treating disorders associated with abnormal phosphate metabolism
11/10/2005US20050249717 Use of hyaluronidase for preventing and treating cardio vascular diseases
11/10/2005US20050249713 Dietary supplement energy-providing to skeletal muscles and protecting the cardiovascular tract
11/10/2005US20050249712 Methods for use of TSLP and agonists and antagonists thereof
11/10/2005US20050249710 biodegradable drug delivery system containing an immunosuppressive agent and a bioerodible polymer comprising hydroxyaliphatic carboxylic acids, and polysaccharides
11/10/2005US20050249708 Cerebral Intraventricular Transplantation as Method of Treating Amyotrophic Lateral Sclerosis (ALS)
11/10/2005US20050249704 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
11/10/2005US20050249702 (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
11/10/2005US20050249700 Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
11/10/2005US20050249697 Compositions and methods for the inhibition of bone growth and resorption
11/10/2005US20050249696 Functionalized organic oligomers using homogeneous modification method for molecular binding
11/10/2005US20050249694 Methods and articles for maintaining hydantoinylated polymers in a biocidally active state
11/10/2005US20050249675 Mucin synthesis inhibitors
11/10/2005US20050249674 aerosol composition comprising a propellant and a first particulate material comprising particles having a median aerodynamic diameter with the range 0.05 to 11 mu m, such as a medicament suitable for pulmonary inhalation, and a second particulate material comprising particles having a median volume
11/10/2005US20050249669 Quadruplex stabilizer
11/10/2005US20050249663 Coadministration of transport protein with conjugated cobalamin to deliver agents
11/10/2005US20050249398 Rapid and robust 3D/3D registration technique
11/10/2005US20050247312 Medicament dispenser
11/10/2005DE10350194B4 Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen Use of extracts of Opuntia for the treatment of depressive disorders and diseases
11/10/2005DE102004019540A1 Composition, useful for treatment of e.g. inflammatory and obstructive respiratory complaint, sinus rhythm in heart in atrioventricular block and circulatory shock, comprises 6-hydroxy-4H-benzo1,4oxazin-3-one derivatives and other actives
11/10/2005DE102004019539A1 Neue Arzneimittel zur Behandlung von Atemwegserkrankungen New drugs for the treatment of respiratory disorders
11/10/2005DE102004019492A1 Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel Selected CGRP antagonists, processes for their preparation and their use as medicaments
11/10/2005DE102004019276A1 New cyanopyrrolizine derivatives, used e.g. for lowering blood sugar, treating type 2 diabetes, treating disorders of lipid and carbohydrate metabolism, treating arteriosclerotic symptoms
11/10/2005DE102004016020A1 Amphoteric liposomal formulations, especially for parenteral applications, contains at least one active substance and neutral lipids as the liposomes with serum stability
11/10/2005DE10112926B4 Verwendung von Aminooxyacetat zur Tumorbehandlung Use of aminooxyacetate for tumor treatment
11/10/2005CA2755954A1 Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists
11/10/2005CA2692561A1 Method for producing solifenacin or salts thereof
11/10/2005CA2686815A1 Therapeutic antimicrobial compositions and methods
11/10/2005CA2649054A1 Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
11/10/2005CA2606443A1 Antimicrobial composition
11/10/2005CA2582265A1 Buccal, polar and non-polar sprays containing propofol
11/10/2005CA2579767A1 Oral pharmaceutical composition in timed-release particle form and fast-disintegrating tablets containing this composition
11/10/2005CA2568436A1 Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor
11/10/2005CA2566369A1 Pentenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
11/10/2005CA2566196A1 Arylsulfonyl benzodioxanes useful for modulating the 5-ht6 receptor, the 5-ht2a receptor or both
11/10/2005CA2565941A1 Improved nsaid composition
11/10/2005CA2565832A1 Preparation for the treatment cancer
11/10/2005CA2565628A1 The combination of prostaglandin e2 receptor antagonist and renin-angiotensin system inhibitor for treating renal diseases
11/10/2005CA2565626A1 Compositions for progeny gender control
11/10/2005CA2565134A1 Novel oral formulations of ospemifene
11/10/2005CA2565054A1 Functionalised siloxanes for scar tissue treatment
11/10/2005CA2565037A1 Purine derivatives as a1 adenosine receptor antagonists
11/10/2005CA2565024A1 Therapeutic agent for left ventricular diastolic dysfunction
11/10/2005CA2565018A1 Fused quinoline derivative and use thereof
11/10/2005CA2565013A1 Method for producing pentacyclic taxans
11/10/2005CA2564994A1 Substituted morpholine compounds for the treatment of central nervous system disorders
11/10/2005CA2564877A1 Formulation comprising histone deacetylase inhibitors
11/10/2005CA2564737A1 Contrast agents for myocardial perfusion imaging
11/10/2005CA2564731A1 Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases
11/10/2005CA2564687A1 Bone substitute compositions and method of use
11/10/2005CA2564604A1 Methods of diminishing co-abuse potential
11/10/2005CA2564603A1 Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
11/10/2005CA2564589A1 Tri-substituted ureas as cytokine inhibitors
11/10/2005CA2564587A1 Tri-substituted ureas as cytokine inhibitors
11/10/2005CA2564564A1 Fluorinated 4-azasteroids as androgen receptor modulators
11/10/2005CA2564561A1 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity
1 ... 4474 4475 4476 4477 4478 4479 4480 4481 4482 4483 4484 4485 4486 4487 4488 4489 4490 4491 4492 4493 4494 ... 7860